Andere talen Ensysce Biosciences, Inc.

Aandelen

ENSC

US2936024056

Vertraagde tijd Nasdaq Andere beurzen 15:56:28 13-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,5818 ^USD	+11,04%		+2,47%	-45,28%

21/03	Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024
15/03	Ensysce Biosciences, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ensysce Biosciences Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published	22/04
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	10/04
Ensysce Biosciences : Corporate Overview	28/03
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Ensysce Biosciences Receives Positive Nasdaq Listing Determination	28/02
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	21/02
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	15/02
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds	14/02
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference	07/02
Ensysce Shares Rally After FDA Feedback on Pain Medication	31/01
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	31/01
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting	26/01
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR	24/01
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	23/01
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	23/01
Ensysce Biosciences Issues 2024 Shareholder Letter	09/01
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023	20/12
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic	15/12
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	14/12
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ensysce Biosciences, Inc.

Aandelen

ENSC

US2936024056

Andere talen

Filters